


Through its clinical pipeline, Novocure strives to extend survival in some of the most aggressive forms of cancer



¹In collaboration with MSD; ²In collaboration with Zai Lab.

References
 1. ClinicalTrials.gov. [NCT04471844]. 2. ClinicalTrials.gov. [NCT04492163]. 3. ClinicalTrials.gov. [NCT02831959]. 4. ClinicalTrials.gov. [NCT02973789]. 5. Novocure. <https://www.novocure.com/novocure-announces-clinical-trial-collaboration-with-msd-to-evaluate-tumor-treating-fields-together-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer/>. Published July 15, 2020. Accessed March 9, 2021. 6. ClinicalTrials.gov. [NCT03377491]. 7. ClinicalTrials.gov. [NCT03606590]. 8. ClinicalTrials.gov. [NCT04281576]. 9. ClinicalTrials.gov. [NCT03940196].
 Note: Information from ClinicalTrials.gov accessed March 9, 2021.

These are investigational trials. Tumor Treating Fields (TTFields) are approved in the United States and CE marked in Europe for the treatment of adults with glioblastoma multiforme and of adults with malignant pleural mesothelioma. TTFields are not approved by the US Food & Drug Administration or CE marked in Europe for the treatment of brain metastasis, pancreatic cancer, hepatocellular carcinoma, gastric adenocarcinoma, or ovarian cancer. TTFields are not approved in the United States for the treatment of lung cancer. TTFields are CE marked in Europe for the treatment of advanced non-small lung cancer.

© 2021 Novocure GmbH. All rights reserved. Novocure is a registered trademark of Novocure GmbH. US-SRC-0366-V4.0. March 2021.